太极TAIJI品牌怎么样 申请店铺

更新时间:2024-07-14
太极TAIJI是哪个国家的品牌?「太极TAIJI」是重庆太极实业(集团)股份有限公司旗下著名品牌。该品牌发源于重庆,由创始人白礼西在1992期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
太极TAIJI怎么样

太极集团有限公司(简称太极集团)是中国企业500强之一,中国医药工业10强,资产200亿元,拥有“太极集团”(重庆太极实业(集团)股份有限公司)、“桐君阁”(重庆桐君阁股份有限公司)两家上市公司。“太极”(TAIJI)为中国首批驰名保护,OTC品牌药企第一名,2014年集团销售总额达230亿元,2021年将跨越千亿大关。

太极集团拥有10000家药房、13000名员工、20多家医药商业公司、13家制药厂及太极医药研究院、重庆中药研究院两大研发机构。1998年,太极集团与国内外15所院校合作建立博士后工作站;1999年,太极集团技术中心被认定为国家级企业技术中心;2013年,获国家批准建立太极院士专家工作站,中国工程院近20位院士成为太极研发顾问。

太极集团现有中西药品种1500多个、全国独家生产品种50多个、获得国家中药保护品种50多个、国家基药品种165个,获国家专利120项、年销售额逾亿元的品种15个。

太极集团的快速发展主要得益于日益增强的科研开发能力,日益完善的国内市场网络,日益成熟的信息化管理,先进的生产装备,畅销的外贸营销渠道,一流的员工队伍和管理团队,颇具中国特色的管理经验。更为重要的是,太极员工多年受“忠诚、责任、团结、努力”的太极精神熏陶,充满了“光大太极、振兴中华”的必胜信念。

习近平、张德江、江泽民、李鹏、温家宝、吴邦国、曾庆红、邹家华等党和国家领导人多次亲临太极集团视察工作,充分肯定太极集团的发展壮大之路,江泽民同志亲笔书写“太极集团”四个金光闪闪的大字予以鼓励。

阴阳互根方能相长,阴阳平衡万事万物方能和谐发展。太极集团渴望交流,期待合作,愿和您为中国医药事业走向世界而共同努力!

太极急支糖浆

批准文号:国药准字Z33020852

药品规格:每瓶装100毫升、200毫升

功能与主治:清热化痰、宣肺止咳。用于外感风热所致的咳嗽,症见发热、恶寒、胸膈满闷、咳嗽咽痛;急性支气管炎、慢性支气管炎急性发作见上述症候者。

用法与用量:口服。一次20~30ml,一日3~4次;儿童一岁以内一次5ml,一岁至三岁一次7ml,三岁至七岁一次10ml,七岁以上一次15ml,一日3~4次。

生产厂家:太极集团浙江东方制药有限公司

太极天胶

批准文号:国药准字Z62021196

药品规格:250克/盒

功能与主治:补血滋阴,润燥,止血。用于血虚萎黄,眩晕心悸,心烦不眠,肺燥咳嗽。

用法与用量:烊化兑服,3—9克

生产厂家:太极集团甘肃天水羲皇阿胶有限公司

Taiji Group Co., Ltd. (hereinafter referred to as Taiji Group) is one of the top 500 Chinese enterprises, one of the top 10 Chinese pharmaceutical industries, with assets of 20 billion yuan. It has two listed companies, Taiji Group (Chongqing Taiji industry (Group) Co., Ltd.) and TongJunGe (Chongqing TongJunGe Co., Ltd.). Taiji is one of the first batch of well-known protection companies in China, and the first OTC brand pharmaceutical enterprise. In 2014, the group's total sales reached 23 billion yuan, and in 2021, it will surpass 100 billion. Taiji Group has 10000 pharmacies, 13000 employees, more than 20 pharmaceutical commercial companies, 13 pharmaceutical factories, Taiji Pharmaceutical Research Institute and Chongqing Traditional Chinese Medicine Research Institute. In 1998, Taiji Group cooperated with 15 universities at home and abroad to establish a postdoctoral workstation; in 1999, Taiji Group Technology Center was recognized as a national enterprise technology center; in 2013, Taiji Group Technology Center was approved by the state to establish a Taiji academician expert workstation, and nearly 20 academicians of Chinese Academy of Engineering became Taiji R & D consultants. Taiji Group has more than 1500 varieties of Chinese and Western medicine, more than 50 national exclusive production varieties, more than 50 national protected varieties of traditional Chinese medicine, 165 national basic medicine varieties, 120 national patents, and 15 varieties with annual sales of more than 100 million yuan. The rapid development of Taiji Group is mainly due to the increasing research and development ability, the increasingly perfect domestic market network, the increasingly mature information management, advanced production equipment, the best-selling foreign trade marketing channels, the first-class staff and management team, and quite unique management experience in China. What's more, Taiji employees have been influenced by Taiji spirit of "loyalty, responsibility, unity and hard work" for many years, and are full of the belief of "Everbright Taiji and rejuvenation of China". Xi Jinping, Zhang Dejiang, Jiang Zemin, Li Peng, Wen Jiabao, Wu Bangguo, Zeng Qinghong, Zeng Qinghong and other party and state leaders visited Tai Chi Group for many times to inspect the work of Taiji group and fully affirmed the development and expansion of Taiji group. Comrade Hu personally wrote the four golden glittering characters of Taiji group to encourage them. Only when Yin and yang are mutually rooted can they grow, and when Yin and yang balance everything, can everything develop harmoniously. Taiji Group is eager to communicate and cooperate with you. We are willing to work with you for the development of Chinese medicine in the world! Approval No. of taijijijizhi syrup: gyzz z33020852 drug specification: 100ml and 200ml per bottle function and indications: clearing heat and resolving phlegm, promoting lung and relieving cough. It is used for cough caused by exogenous wind heat. Symptoms include fever, cold, chest and diaphragm fullness, cough and sore throat; acute bronchitis and chronic bronchitis with acute attack. Usage and dosage: oral. 20-30ml for one time, 3-4 times a day; 5ml for children under one year old, 7ml for children from one to three years old, 10ml for children from three to seven years old, 15ml for children over seven years old, 3-4 times a day. Manufacturer: Taiji Tianjiao of Zhejiang Oriental Pharmaceutical Co., Ltd. of Taiji group approval No.: gyzz z62021196 drug specification: 250G / box function and indications: nourishing blood and Yin, moistening dryness, hemostasis. It is used for deficiency of blood, yellowing, vertigo, palpitation, restlessness, lung dryness and cough. Usage and dosage: shunyua mixed service, 3-9g manufacturer: Taiji Group Gansu Tianshui Xihuang donkey hide gelatin Co., Ltd

本文链接: https://brand.waitui.com/0814962ca.html 联系电话:023-72800072

7×24h 快讯

债市“降温” 短期内波动或仍将持续

7月以来,债基产品收益表现出现明显震荡。数据显示,截至7月12日,超1000只债基月内回报为负。多位业内人士表示,今年以来债券市场持续火热,长期债券利率下降显著。为抑制过热的市场情绪,保障市场长期稳健发展,央行于近期开展系列操作。展望后市,短期内债市波动或仍将持续,市场情绪偏向谨慎,偏防御性的中短端资产或相对占优。(中国基金报)

25分钟前

安利股份:上半年净利同比预增9348.14%—10421.8%

安利股份发布业绩预告,预计上半年净利为8800万元—9800万元,同比增长9348.14%—10421.8%。报告期内,公司主营产品销量同比增长约19.7%,销售收入同比增长约29.1%。公司主营业务发展态势良好,毛利率较上年同期实现大幅提升,利润增长。(新浪财经)

25分钟前

汇金通:半年度净利润5250万到6200万元 增加107.83%到145.43%

汇金通披露2024年半年度业绩预增公告,该公司预计报告期归属于上市公司股东的净利润为5250万元到6200万元,同比增加107.83%到145.43%。归属于上市公司股东的扣除非经常性损益的净利润为4990.53万元到5940.53万元,同比增加288.35%到362.27%。报告期内,公司持续强化成本管控,优化内部管理,积极提升运营效率,规模效益显现。主营产品产销量较上年同期有较大幅度增长,主要原材料价格较上年同期有所下降,主营产品毛利率有所回升。(新浪财经)

26分钟前

中伟股份:上半年归母净利同比预增8.04%—21.06%

中伟股份7月14日晚间发布业绩预告,预计上半年净利润11.3亿元—12.3亿元,同比增长33.76%—45.6%;归母净利润8.3亿元至9.3亿元,同比增长8.04%—21.06%。公司四大材料体系产品出货量持续保持正向增长,报告期内,镍、钴、磷、钠四系产品销售量超14万吨,同比增长15%,公司主要产品市场占有率持续保持领先。报告期内,公司印尼镍产品整体产出超3.5万金属吨,其中第二季度环比增长39%,后续随着印尼镍冶炼项目产能放量,将推动公司效益进一步提升。(新浪财经)

26分钟前

蓝晓科技:上半年净利润同比预增13.96%—18.45%

蓝晓科技7月14日晚间发布业绩预告,预计2024年半年度净利润3.94亿元—4.1亿元,同比增长13.96%—18.45%。报告期内,公司吸附分离材料销售保持良好增长,国际市场竞争力进一步提升。生命科学、提锂订单持续拓展、超纯水领域产品销售规模增加。(新浪财经)

26分钟前

本页详细列出关于太极TAIJI的品牌信息,含品牌所属公司介绍,太极TAIJI所处行业的品牌地位及优势。
咨询